Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779531 | 0.88 | KCNA3 (0.44) | KCNA3PLK1BRD4HTR7NPY5R | |
| SCHEMBL3859391 | 0.85 | KCNA3 (0.42) | KCNA3PLK1BRD4HTR7NPY5R | |
| SCHEMBL4302247 | 0.82 | KCNA3 (0.49) | KCNA3PLK1BRD4NPY5RCNR2 | |
| SCHEMBL4301542 | 0.79 | CNR2 (0.45) | CNR2DRD3 | |
| SCHEMBL12002142 | 0.77 | KCNH2 (0.49) | KCNA3NPY5R | |
| SCHEMBL4300063 | 0.76 | CNR2 (0.48) | CNR2CNR1DRD2DRD3HTR2A | |
| SCHEMBL4294604 | 0.76 | KCNH2 (0.42) | CCR5HTR2A | |
| SCHEMBL3839979 | 0.76 | MCHR1 (0.44) | CNR2DRD2DRD3HTR2A | |
| SCHEMBL27780828 | 0.75 | DRD2 (0.40) | PLK1DRD2DRD3 | |
| SCHEMBL5021645 | 0.74 | KCNH2 (0.55) | KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | KCNA3 1771/4885CCR5 2505/4885PLK1 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.